# Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

> **NCT05011513** · PHASE2,PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 1440 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** PF-07321332
- **DRUG:** Ritonavir
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05011513
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-25
- **Primary completion:** 2022-07-25
- **Final completion:** 2022-07-25
- **Target enrollment:** 1440 (ACTUAL)
- **Why stopped:** Enrollment ceased due to a very low rate of hospitalization or death observed in the standard-risk patient population
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05011513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05011513, "Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05011513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*